These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 36804350)

  • 41. Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province.
    Sadek J; Saunders J
    BMC Psychiatry; 2022 Jul; 22(1):516. PubMed ID: 35908052
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Higher First 30-Day Dose of Buprenorphine for Opioid Use Disorder Treatment Is Associated With Decreased Mortality.
    Lei F; Lofwall MR; McAninch J; Adatorwovor R; Slade E; Freeman PR; Moga DC; Dasgupta N; Walsh SL; Vickers-Smith R; Slavova S
    J Addict Med; 2024 May-Jun 01; 18(3):319-326. PubMed ID: 38598300
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association of a Multimodal Educational Intervention for Primary Care Physicians With Prescriptions of Buprenorphine for Opioid Use Disorders.
    Clark B; Kai M; Dix R; White J; Rozenfeld Y; Levy S; Engstrom K
    JAMA Netw Open; 2019 Oct; 2(10):e1913818. PubMed ID: 31642929
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)".
    Shulman M; Weiss R; Rotrosen J; Novo P; Costello E; Nunes EV
    Addict Sci Clin Pract; 2021 Mar; 16(1):15. PubMed ID: 33676577
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial.
    Lintzeris N; Dunlop AJ; Haber PS; Lubman DI; Graham R; Hutchinson S; Arunogiri S; Hayes V; Hjelmström P; Svedberg A; Peterson S; Tiberg F
    JAMA Netw Open; 2021 May; 4(5):e219041. PubMed ID: 33970256
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Polysubstance Use in Adults With Opioid Use Disorder Receiving Buprenorphine Maintenance.
    Elarabi HF; Radwan DN; Adem A; Marsden J; Lee AJ
    J Addict Med; 2023 Jan-Feb 01; 17(1):74-78. PubMed ID: 35793664
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mobile, Community-Based Buprenorphine Treatment for Veterans Experiencing Homelessness With Opioid Use Disorder: A Pilot, Feasibility Study.
    Iheanacho T; Payne K; Tsai J
    Am J Addict; 2020 Nov; 29(6):485-491. PubMed ID: 32367557
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia.
    Burns L; Gisev N; Larney S; Dobbins T; Gibson A; Kimber J; Larance B; Mattick RP; Butler T; Degenhardt L
    Addiction; 2015 Apr; 110(4):646-55. PubMed ID: 25516077
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Effect of a Payer-Mandated Decrease in Buprenorphine Dose on Aberrant Drug Tests and Treatment Retention Among Patients with Opioid Dependence.
    Accurso AJ; Rastegar DA
    J Subst Abuse Treat; 2016 Feb; 61():74-9. PubMed ID: 26639639
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Buprenorphine Medication for Opioid Use Disorder: A Study of Factors Associated With Postpartum Treatment Retention.
    Ray-Griffith S; Tharp E; Coker JL; Catlin D; Knight B; Stowe ZN
    Am J Addict; 2021 Jan; 30(1):43-48. PubMed ID: 32673447
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Buprenorphine Dose and Time to Discontinuation Among Patients With Opioid Use Disorder in the Era of Fentanyl.
    Chambers LC; Hallowell BD; Zullo AR; Paiva TJ; Berk J; Gaither R; Hampson AJ; Beaudoin FL; Wightman RS
    JAMA Netw Open; 2023 Sep; 6(9):e2334540. PubMed ID: 37721749
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Office-Based Buprenorphine Treatment: Identifying Factors That Promote Retention in Opioid-Dependent Patients.
    Noe SR; Keller T
    J Addict Nurs; 2020; 31(1):23-29. PubMed ID: 32132421
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Short communication: Relationship between social determinants and opioid use disorder treatment outcomes by gender.
    Parlier-Ahmad AB; Radic M; Svikis DS; Martin CE
    Drug Alcohol Depend; 2022 Mar; 232():109337. PubMed ID: 35123364
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Acceptability and efficacy of naltrexone for criminal justice-involved individuals with opioid use disorder: a systematic review and meta-analysis.
    Bahji A; Carlone D; Altomare J
    Addiction; 2020 Aug; 115(8):1413-1425. PubMed ID: 31863669
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Associations of retention on buprenorphine for opioid use disorder with patient characteristics and models of care in the primary care setting.
    Bailey SR; Lucas JA; Angier H; Cantone RE; Fleishman J; Garvey B; Cohen DJ; Rdesinski RE; Gordon L
    J Subst Abuse Treat; 2021 Dec; 131():108548. PubMed ID: 34244013
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data.
    Zhang P; Tossone K; Ashmead R; Bickert T; Bailey E; Doogan NJ; Mack A; Schmidt S; Bonny AE
    J Subst Abuse Treat; 2022 May; 136():108686. PubMed ID: 34953637
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prevalence and treatment of opioid use disorders among primary care patients in six health systems.
    Lapham G; Boudreau DM; Johnson EA; Bobb JF; Matthews AG; McCormack J; Liu D; Samet JH; Saxon AJ; Campbell CI; Glass JE; Rossom RC; Murphy MT; Binswanger IA; Yarborough BJH; Bradley KA;
    Drug Alcohol Depend; 2020 Feb; 207():107732. PubMed ID: 31835068
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of lowering initiation thresholds in a primary care-based buprenorphine treatment program.
    Payne BE; Klein JW; Simon CB; James JR; Jackson SL; Merrill JO; Zhuang R; Tsui JI
    Drug Alcohol Depend; 2019 Jul; 200():71-77. PubMed ID: 31103879
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An examination between treatment type and treatment retention in persons with opioid and co-occurring alcohol use disorders.
    Mintz CM; Presnall NJ; Xu KY; Hartz SM; Sahrmann JM; Bierut LJ; Grucza RA
    Drug Alcohol Depend; 2021 Sep; 226():108886. PubMed ID: 34245997
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of Medication for Opioid Use Disorder Among US Adolescents and Adults With Need for Opioid Treatment, 2019.
    Mauro PM; Gutkind S; Annunziato EM; Samples H
    JAMA Netw Open; 2022 Mar; 5(3):e223821. PubMed ID: 35319762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.